All In MedTech

FDA Clearance Tracker · P170003

LUTONIX® 035 Drug Coated Balloon PTA Catheter, Model 9010

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Aug 25, 2017 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Aug 25, 2017

Approved

Time to decision

214 days

Received Jan 23, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P170003
Device name
LUTONIX® 035 Drug Coated Balloon PTA Catheter, Model 9010
Applicant
Lutonix
Applicant location
New Hope, MN
Received
Jan 23, 2017
Decided
Aug 25, 2017
Decision
Approved
Supplements
24 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code PRC

FDA's approval statement

As written in FDA's record.

Approval for the LUTONIX® 035 Drug Coated Balloon PTA Catheter. This device is indicated for percutaneous transluminal angioplasty (PTA), after pre-dilatation, for the treatment of stenotic lesions in dysfunctional native arteriovenous dialysis fistulae that are 4 mm to 12 mm in diameter and up to 80 mm in length.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code PRC (Drug-coated peripheral transluminal angioplasty catheter).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Lutonix

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.